middle.news
Neurizon Clears FDA Hold, Raises $5.2M, Advances ALS Drug NUZ-001
9:46am on Friday 31st of October, 2025 AEDT
•
Biotechnology
Read Story
Neurizon Clears FDA Hold, Raises $5.2M, Advances ALS Drug NUZ-001
9:46am on Friday 31st of October, 2025 AEDT
Key Points
FDA lifts clinical hold on NUZ-001, enabling HEALEY ALS Platform Trial entry
Completed $5.2 million share placement and secured $1.5 million R&D loan
Synchronized global regulatory strategy targets US, Europe, Canada, Japan, Australia
NUZ-001 shows promising preclinical data on protein clearance and neuroprotection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE